Treatment of Takayasu's arteritis with tumor necrosis factor antagonists.
Four children with Takayasu's arteritis were treated with tumor necrosis factor antagonists because of disease relapse during conventional therapy or as a first-line agent. Two patients went into remission; in the other 2, the response was partial. Anti-tumor necrosis factor agents can have a role in the treatment of Takayasu's arteritis; further controlled studies are required.
Filocamo
Giovanni
G
Pediatria II IRCCS G. Gaslini e Dipartimento di Pediatria, Università di Genova, Italy.
Buoncompagni
Antonella
A
Viola
Stefania
S
Loy
Anna
A
Malattia
Clara
C
Ravelli
Angelo
A
Martini
Alberto
A
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D018810:Magnetic Resonance Angiography; D008297:Male; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013625:Takayasu Arteritis / Q000175:diagnosis / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab